Kimia Biosciences Hits New 52-Week Low at Rs. 30.62

Kimia Biosciences has reached a new 52-week low, hitting Rs. 30.62 today, marking a significant downturn for the microcap pharmaceutical and biotechnology company. This decline comes as the stock has underperformed its sector by 0.75% and has experienced a consecutive fall over the past two days, resulting in a total decrease of 1.15% during this period.
The company's performance over the past year has been notably challenging, with a decline of 28.33%, contrasting sharply with the Sensex's positive performance of 5.44%. Kimia Biosciences is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a sustained downward trend.

Financial metrics reveal a concerning picture, with net sales falling by 20.7% compared to the previous quarter's average. Additionally, the company's profitability has also taken a hit, with a 75% decrease in profit after tax. The high debt levels, reflected in a debt-to-equity ratio of 12.14 times, further complicate its financial standing. As the market continues to fluctuate, Kimia Biosciences faces significant challenges in regaining its footing.